Søborg

Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

Tuesday, July 27, 2021 - 9:05pm

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • With the transactions stated above, Zealand owns a total of 218,410 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.5% of the total share capital.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.

Zealand Pharma A/S – Transaction Under Share Repurchase Program

Tuesday, July 20, 2021 - 9:05pm

Company announcement – No. 47 / 2021

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma A/S – Transaction Under Share Repurchase Program

Tuesday, July 13, 2021 - 9:05pm

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.
  • Zealand notes that its announcement of 6 July 2021 incorrectly stated its share capital to be DKK 43,655,061.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.

ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

Tuesday, July 6, 2021 - 4:55pm

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

Key Points: 
  • The details for each transaction made under the share repurchase program are included as an appendix to this announcement.
  • With the transactions stated above, Zealand owns a total of 113,223 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.0026% of the total share capital.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.

Total number of shares and voting rights in Zealand Pharma at June 30, 2021

Wednesday, June 30, 2021 - 3:00pm

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.

Key Points: 
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.
  • The above information contains forward-looking statements that provide Zealand Pharmas expectations or forecasts of future events.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)

Tuesday, June 29, 2021 - 12:00pm

The Companys research presented at CIRTA 2021 will feature multiple posters related to glepaglutide for the treatment of short bowel syndrome (SBS).

Key Points: 
  • The Companys research presented at CIRTA 2021 will feature multiple posters related to glepaglutide for the treatment of short bowel syndrome (SBS).
  • Glepaglutide is being developed as a ready-to-use liquid product in an autoinjector desiged for convenient and easy subcutaneous administration.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.

Zealand Pharma A/S - Share Buy-Back Program Under Safe Harbour to Aquire Danish Common Stock for Employee Incentive Programs

Monday, June 28, 2021 - 9:05pm

On a weekly basis, Zealand will announce transactions made under the share repurchase program in accordance with the reporting obligations imposed by the Safe Harbour Regulation.

Key Points: 
  • On a weekly basis, Zealand will announce transactions made under the share repurchase program in accordance with the reporting obligations imposed by the Safe Harbour Regulation.
  • Zealand may terminate the program at any time, which will be announced through Nasdaq Copenhagen A/S, if relevant.
  • The share buy-back program will start on June 29 , 2021 and will be completed no later than July 29, 2021.
  • Prior to launch of the share repurchase program, Zealand holds 64,223 treasury shares, corresponding to 0.01% of the total share capital.

Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection

Thursday, June 24, 2021 - 12:00pm

We are thrilled to announce that ZEGALOGUE is now available to support people with diabetes and their caregivers, said Frank Sanders, President of U.S. Operations for Zealand Pharma.

Key Points: 
  • We are thrilled to announce that ZEGALOGUE is now available to support people with diabetes and their caregivers, said Frank Sanders, President of U.S. Operations for Zealand Pharma.
  • The commercial availability of ZEGALOGUE brings us one step closer to helping people feel confident and prepared to address the unpredictable nature of severe hypoglycemia.
  • ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
  • 2019;2:e00057
    Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.

Zealand Pharma to Participate in LifeSci Nordic Biotech Summit

Tuesday, June 22, 2021 - 9:05pm

Copenhagen, DK and Boston, MA, U.S. June 22, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. June 22, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the LifeSci Nordic Biotech Summit.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.
  • More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market.

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Wednesday, June 16, 2021 - 1:06pm

Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

Key Points: 
  • Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
    Company to present six abstracts on ZEGALOGUE(dasiglucagon) injection, including one oral presentation
    Copenhagen, DK and Boston, MA, U.S. June 16, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • "We are proud to share such a robust set of clinical data at this years ADA medical meeting, said Adam Steensberg, Executive Vice President, Research & Development of Zealand Pharma.
  • ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines.